TeamDrive
RUS

Deloitte and Vineti join forces to support personalized medicine development

07 September 2018

GMP News

Deloitte and Vineti announced that they have entered into a teaming agreement, announcing their intent to work together to support life sciences innovators by integrating and scaling their respective supply chain and patient engagement platforms to enable more efficient access to next-generation cellular therapies.

Vineti’s cell and gene therapy platform provides a digital “platform of record” for individualized therapies and Deloitte’s ConvergeHEALTH Patient Connect™ platform streamlines and improves patient and health system engagement at pharmaceutical, medical device and hub vendors. Together, the Vineti and ConvergeHEALTH Patient Connect™ platforms can offer a holistic one-stop solution to support life sciences innovators and health care professionals with the information systems to deliver on the promise of personalized medicine.

In individualized medicine, the patient is a key part of the therapeutic process, the product and the treatment. The combination of Vineti’s proven expertise in delivering cell and gene therapies and Deloitte’s deep knowledge of the health care ecosystem and its time-tested (or something similar) ConvergeHEALTH Patient Connect platform will help enable life sciences innovators to expand the role of personalized medicines in mainstream health care.

Vineti is the first cloud-based software platform to safely and efficiently move patient-based personalized therapies into mainstream medicine at scale. The Vineti platform – configurable, cloud-based, secure and scalable – brings the best of enterprise software to next-generation pharmaceutical science. Vineti’s solution aligns, manages, integrates and simplifies all the major steps and stakeholders in the inherently complex cell and gene therapy process, helping everyone from health care providers to biopharma and manufacturers exert efficiency and control to optimize the patient’s therapy journey. The Vineti platform is currently serving patients in more than 65 leading medical centers and expanding worldwide.

ConvergeHEALTH Patient Connect currently supports more than 300,000 patients globally in over 17 countries. Deloitte’s ConvergeHEALTH suite of software solutions are built with the understanding that, in today’s market, truly actionable insights are derived from a combination of real-world information, evidence and experience, not just data. Powered by Deloitte’s virtually unparalleled industry experience, the ConvergeHEALTH solutions are designed specifically to solve the biggest business and operational challenges that the health care and life science industries face.

By working with Vineti and ConvergeHEALTH by Deloitte, life sciences innovators will be able to scale their personalized therapies, connect with even more health care providers, and provide more therapies to more patients than ever before.

Headquartered in UK, Deloitte Touche Tohmatsu Limited is a multinational professional services network and one of the “Big Four” accounting organizations and the largest professional services network in the world by revenue and number of professionals.

Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by multinational conglomerate General Electric (Boston, USA) and the Mayo Clinic (Rochester, Minnesota, USA) to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies.


Previous publication Next publication

Media Center

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

  • 18 October 2018

    Russia emerges as frontrunner in global fight against tuberculosis

    Russia has turned out to be the world’s most successful tuberculosis fighter, Russian Health Minister Veronika Skvortsova stated  during the interview with the Rossiya-24 channel. "We are the global leader according to the pace in solving this issue," she noted, adding, "all countries acknowledge Russia’s foremost role here."

  • 17 October 2018

    Scientists developed new tool for open exchange of biomaterials

    A new easy-to-use legal tool that enables open exchange of biological materials was launched. The OpenMTA is a Material Transfer Agreement (MTA) designed to support openness, sharing and innovation in global biotechnology. Material Transfer Agreements (MTAs) provide the legal frameworks within which research organisations define terms and conditions for sharing their materials – everything from DNA molecules to plant seeds to patient samples.

  • 16 October 2018

    The First FDA-approved Digital Pill — What It Means for Pharma

    Last year, the U.S. Food and Drug Administration (FDA) approved what is perhaps the boldest use of digital technology in healthcare: a pill that is integrated with an ingestible sensor that captures information about whether the patient has complied with her medication regimen. A patient ingests the pill and it sends the data to a patch worn on her torso, which adds various physiologic measures. From there the information is wirelessly sent to a mobile phone app, allowing both the patient and her physician to track how the patient is using and responding to her medication.

Read more